In a shocking turn of events, the Food and Drug Administration’s (FDA) top drug regulator has stepped down amidst a cloud of controversy, leaving many to wonder: What really happened behind closed doors? Dr. George Tidmarsh, who assumed the role in July, resigned abruptly on Sunday following an investigation into “serious concerns about his personal conduct,” as revealed by a government spokesperson. But here’s where it gets even more intriguing—his resignation came on the heels of a lawsuit filed by Aurinia Pharmaceuticals, accusing him of using his FDA position to settle old scores with a former business associate. And this is the part most people miss: Tidmarsh’s departure is just the latest in a series of chaotic leadership changes at the FDA, an agency already reeling from firings, resignations, and contentious decisions on vaccines, fluoride, and more.
The drama began when Tidmarsh was placed on leave Friday after officials in the Department of Health and Human Services’ (HHS) Office of General Counsel were alerted to unspecified issues. By Sunday morning, he had resigned. HHS press secretary Emily Hilliard emphasized that Secretary Kennedy demands the highest ethical standards and remains committed to transparency. Yet, the timing of Tidmarsh’s exit raises eyebrows, as it coincided with Aurinia’s lawsuit alleging he made “false and defamatory statements” during his brief tenure at the FDA.
According to the lawsuit, Tidmarsh allegedly leveraged his position to pursue a personal vendetta against Kevin Tang, chair of Aurinia’s board. Tang had previously played a role in Tidmarsh’s ouster from leadership positions at other pharmaceutical companies, including La Jolla Pharmaceutical. Is this a case of professional retaliation, or is there more to the story? The lawsuit also claims Tidmarsh targeted a thyroid drug made by American Laboratories, another company chaired by Tang. Aurinia’s stock plummeted 20% after Tidmarsh publicly criticized one of its kidney drugs on LinkedIn, a highly unusual move for an FDA regulator. Tidmarsh later deleted the post, claiming it was made in a personal capacity, not as an FDA official.
Before joining the FDA, Tidmarsh was a seasoned figure in California’s pharmaceutical and biotech industries, founding and leading multiple companies. He also served as an adjunct professor at Stanford University. His recruitment to the FDA came after meeting with Commissioner Marty Makary. However, his tenure was short-lived and marked by turmoil, mirroring broader instability at the agency. For instance, Dr. Vinay Prasad, head of the FDA’s vaccine and biologics center, resigned in July under pressure from conservative activists, only to return two weeks later at the urging of Health Secretary Robert F. Kennedy Jr.
The FDA’s drug center, which Tidmarsh oversaw, has seen over 1,000 staffers leave in the past year due to layoffs or resignations. This division is critical, responsible for reviewing the safety and quality of prescription and over-the--counter medicines. Tidmarsh’s LinkedIn post about Aurinia’s kidney drug not only sparked controversy but also wiped out over $350 million in shareholder value, according to the lawsuit. Aurinia is now seeking compensatory and punitive damages in the U.S. District Court of Maryland, aiming to “set the record straight.”
But here’s the bigger question: What does this say about the FDA’s leadership and its ability to function effectively? With repeated scandals and high-profile departures, the agency’s credibility is on the line. Is this a systemic issue, or just a series of unfortunate events? We want to hear from you—do you think Tidmarsh’s actions were justified, or was he out of line? Share your thoughts in the comments below. A free press is a cornerstone of a healthy democracy, and your voice matters in this critical conversation.
